These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25397423)

  • 1. Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy.
    Erdbeer G; Sabranski M; Sonntag I; Stoehr A; Horst HA; Plettenberg A; Schewe K; Unger S; Stellbrink HJ; Fenske S; Hoffmann C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19673. PubMed ID: 25397423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matter.
    Erdbeer G; Sabranski M; Sonntag I; Stoehr A; Horst HA; Plettenberg A; Schewe K; Unger S; Stellbrink HJ; Fenske S; Hoffmann C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19689. PubMed ID: 25397439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy.
    Sabranski M; Erdbeer G; Sonntag I; Stoehr A; Horst HA; Plettenberg A; Lebherz L; Stellbrink HJ; Hoffmann C
    AIDS Care; 2021 Apr; 33(4):453-461. PubMed ID: 32106695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
    Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
    Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines.
    Bhargav H; Huilgol V; Metri K; Sundell IB; Tripathi S; Ramagouda N; Jadhav M; Raghuram N; Ramarao NH; Koka PS
    J Stem Cells; 2012; 7(3):127-53. PubMed ID: 23619381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced HIV symptoms and improved health-related quality of life correlate with better access to care for HIV-1 infected women: the ELLA study.
    Baran R; Mulcahy F; Krznaric I; Monforte Ad; Samarina A; Xi H; Cassetti I; Madruga JV; Zachry W; van Wyk J; Martinez M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19616. PubMed ID: 25394120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
    Podzamczer D; Rozas N; Domingo P; Ocampo A; Van den Eynde E; Deig E; Vergara A; Knobel H; Pasquau J; Antela A; Crespo M; Clotet B; Muñoz J; Fernandez P; Geijo P; de Castro ER; Diz J; Casado A; Torres C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19814. PubMed ID: 25397558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
    Bloch M; Farris M; Tilden D; Gowers A; Cunningham N
    Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort.
    Wolf E; Trein A; Baumgarten A; Stephan C; Jaeger H; Hillenbrand H; Koeppe S; Lutz T; Koenig B; Stellbrink HJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19770. PubMed ID: 25397514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.
    Sungkanuparph S; Chakriyanuyok T; Butthum B
    J Infect; 2008 Jan; 56(1):40-3. PubMed ID: 18037166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
    HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
    Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
    Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.